-
Duncan Williams Upgrades Salix Pharmaceuticals To Buy, $47 PT
Tuesday, July 5, 2011 - 7:10am | 26Duncan Williams has upgraded Salix Pharmaceuticals (NASDAQ: SLXP) from Hold to Buy and has established a $47 price target.
-
Stocks To Watch For July 5
Tuesday, July 5, 2011 - 4:05am | 181Some of the stocks that may grab investor focus today are: The New York Times Company (NYSE: NYT) sold more than half of its minority ownership in the Boston Red Sox. NYT shares dropped 0.11% to close at $8.71 on Friday. Whirlpool Corp (NYSE: WHR) said that the United States District Court of...
-
3 High Momentum Stocks to Watch This Week
Monday, July 4, 2011 - 9:18pm | 3872Each week I publish stocks to watch for the upcoming week as potential momentum trades or longer-term investments. The stocks below all have a 50k minimum average daily share volume and traded at a 52-week high on strong volume, with a minimum of two times relative volume on Friday, July 1st. In...
-
Momentum Stocks For Next Week
Saturday, July 2, 2011 - 5:26pm | 2032( click to enlarge ) Motorola Mobility Holdings Inc (NYSE:MMI) has printed a bullish engulfing candlestick pattern on Friday. May be this is the right time to see a more significant rebound. Volume starts to pick up. Could make a huge move to the upside. Looks like we might bounce back into...
-
Sideline Money Flows In 07-01-2011
Friday, July 1, 2011 - 2:55pm | 997Cusick's Corner Buyers prevail. The sideline money is flowing into the market and it did it early on the heels of inline data this morning. The market is trending nicely, above the 50-Day Moving Average, taking back most of the pullback from the April highs, and this latest move is happening in...
-
Jefferies Has Hold On Avanir Pharmaceuticals
Friday, July 1, 2011 - 1:29pm | 84Jefferies & Co. has a Hold rating and a $3.50 price target on shares of Avanir Pharmaceuticals (NASDAQ: AVNR). In the note, Jefferies writes, "Notice of a Paragraph IV certification challenging AVNR's Nuedexta appeared on the FDA website on 6/30. While we had been anticipating a Paragraph IV...
-
Time To Look At Boston Scientific?
Friday, July 1, 2011 - 1:10pm | 351Boston Scientific Corporation (NYSE: BSX) shares are up 3% today, but the real move may come if the Natick-based company gets purchased. At nearly $11 billion, Boston Scientific is not cheap for an acquirer, but the company does have a product, stents, that may be attractive to an acquirer....
-
Friday's Put/Call Ratio Leaders
Friday, July 1, 2011 - 12:44pm | 78Here are today's Put/Call Ratio leaders… 1. Pharmacyclics Inc. (NASDAQ: PCYC) 3,550 puts, 19 calls 2. Beazer Homes (NYSE: BZH) 5,000 puts, 100 calls 3. Carters Inc. (NYSE: CRI) 3,900 puts, 136 calls 4. Cadence Pharmaceuticals (NASDAQ: CADX) 5,704 puts, 204 calls 5. Titanium Metals Corp. (NYSE: TIE...
-
Shire Files Lawsuits Against Sandoz and Amneal for Infringement of VYVANSE Patents
Friday, July 1, 2011 - 12:04pm | 116Shire plc (NASDAQ: SHPGY) announces that it has filed lawsuits in the U.S. District Court for the District of New Jersey against each of Amneal Pharmaceuticals, LLC and Sandoz, Inc. for infringement of certain of Shire's VYVANSE patents. The lawsuits were initiated in response to Abbreviated New...
-
Options Brief: Cadence Pharmaceuticals
Friday, July 1, 2011 - 11:17am | 72Shares of Cadence Pharmaceuticals (NASDAQ: CADX) are higher on the session by 1.85%, trading at $9.37. Overall put volume is now running at 25.01x the daily average, with 4% of all puts traded being purchases on the offer. 5,678 contracts have traded on the session so far. Cadence...
-
Wells Fargo Maintains Market Perform on Eli Lilly
Friday, July 1, 2011 - 9:33am | 106Wells Fargo is out with its report today on Eli Lilly (NYSE: LLY), maintaining Market Perform. In a note to clients, Wells Fargo writes, "Investor day highlights pipeline candidates in diabetes, oncology, neurology, and autoimmune. Management reiterated 2011-14 minimum annual guidance of $20B in...
-
Avanir Pharmaceuticals Announces Paragraph IV ANDA Filing for NUEDEXTA
Friday, July 1, 2011 - 8:30am | 179Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that the U.S. Food and Drug Administration website indicates that an Abbreviated New Drug Application for a generic version of NUEDEXTA (dextromethorphan hydrobromide and quinidine sulfate) capsules was submitted on March 7, 2011. The...
-
Benzinga's Top Downgrades
Friday, July 1, 2011 - 8:11am | 144Analysts at Deutsche Bank downgraded Advisory Board Company (NASDAQ: ABCO) from “buy” to “hold.” ABCO's stock closed at $57.88 yesterday. Advisory Board's PEG ratio is 1.55. Analysts at JP Morgan downgraded BioMimetic Therapeutics Inc (NASDAQ: BMTI) from “overweight” to “neutral.” BMTI 's shares...
-
J.P. Morgan Comments On Eli Lilly Investor Day
Friday, July 1, 2011 - 7:54am | 119According to J.P. Morgan, Eli Lilly & Company (NYSE: LLY) investor day focused on the assumptions supporting the company's $20bn/$3bn trough sales and net income assumptions as well as Lilly's late stage pipeline aimed at accelerating growth off these trough levels. J.P. Morgan said that it...
-
News Summary for July 1, 2011
Friday, July 1, 2011 - 7:53am | 392This is your Benzinga news summary and traders' outlook for Friday, July 1, 2011, covering headlines from overnight and Friday's pre-market session. Today in domestic pre-market trading, U.S. equity futures and the U.S. dollar are trading relatively flat as traders wait for key economic data to be...